Nuformix announced that it has appointed Dr. Christopher Blackwell as a Non-executive Director. The appointment reflects Nuformix's ambition and trajectory as it embarks on a period of growth, building on its position of developing innovative cocrystal-based therapies. Chris joins the Board with immediate effect. Dr. Chris Blackwell, B.Sc, Ph.D. served as CEO of Vectura Group Plc from February 2004 to June 2015, taking the company through its initial IPO to a valuation of over $1 billion.